Liu Gang, Pan Liang-Zhi, Chen Jie, Ma Jianying
Department of Thyroid and Breast Surgery, The People's Hospital of Suzhou New District, Suzhou, China.
Party Committee Office, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.
Breast Cancer Res Treat. 2025 May;211(1):35-50. doi: 10.1007/s10549-025-07620-x. Epub 2025 Jan 28.
The heterogeneity of breast cancer (BC) necessitates the identification of novel subtypes and prognostic models to enhance patient stratification and treatment strategies. This study aims to identify novel BC subtypes based on PANoptosis-related genes (PRGs) and construct a robust prognostic model to guide individualized treatment strategies.
The transcriptome data along with clinical data of BC patients were sourced from the TCGA and GEO databases. Consensus clustering was performed on 12 PRGs to ascertain potential BC subtypes, and variances in survival, infiltration of immune cells, and functional pathways among them were examined. A prognostic model was generated through 101 combinations of machine learning algorithms and validated across multiple cohorts. The response of patients towards immunotherapy were analyzed using multiple frameworks.
Consensus clustering of 12 PRGs identified two distinct BC subtypes, with subtype B exhibiting significantly lower overall survival (OS) rates compared to subtype A. Immune cell infiltration analysis revealed higher immune activity in subtype A. Functional pathway analysis revealed that subtype A exhibited a significant enrichment in immune-related pathways, while subtype B was associated with cell cycle and metabolic processes. An integrated machine learning framework integrating CoxBoost and Random Survival Forest (RSF) algorithms was developed, demonstrating high predictive performance across multiple cohorts. A nomogram combining age and risk score was constructed, showing excellent predictive performance. Immune landscape analysis revealed that the high-risk group exhibited a suppressive tumor immune microenvironment (TIME). Immunotherapy response prediction suggested that low-risk patients were more likely to benefit from PD-1 and CTLA-4 inhibitors.
Our study provides a comprehensive framework for BC subtype classification and prognostic prediction, offering valuable insights for personalized treatment strategies.
乳腺癌(BC)的异质性使得有必要识别新的亚型和预后模型,以加强患者分层和治疗策略。本研究旨在基于泛凋亡相关基因(PRGs)识别新的BC亚型,并构建一个强大的预后模型以指导个体化治疗策略。
BC患者的转录组数据及临床数据来自TCGA和GEO数据库。对12个PRGs进行一致性聚类,以确定潜在的BC亚型,并检查它们之间在生存、免疫细胞浸润和功能通路方面的差异。通过机器学习算法的101种组合生成预后模型,并在多个队列中进行验证。使用多种框架分析患者对免疫治疗的反应。
12个PRGs的一致性聚类确定了两种不同的BC亚型,与A亚型相比,B亚型的总生存率(OS)显著较低。免疫细胞浸润分析显示A亚型具有更高的免疫活性。功能通路分析显示,A亚型在免疫相关通路中显著富集,而B亚型与细胞周期和代谢过程相关。开发了一个整合CoxBoost和随机生存森林(RSF)算法的机器学习框架,在多个队列中显示出高预测性能。构建了一个结合年龄和风险评分的列线图,显示出优异的预测性能。免疫景观分析显示,高风险组表现出抑制性肿瘤免疫微环境(TIME)。免疫治疗反应预测表明,低风险患者更有可能从PD-1和CTLA-4抑制剂中获益。
我们的研究为BC亚型分类和预后预测提供了一个全面的框架,为个性化治疗策略提供了有价值的见解。